FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4386020163> ?p ?o ?g. }

• W4386020163 endingPage "736" @default.
• W4386020163 startingPage "727" @default.
• W4386020163 abstract "First-line immune checkpoint blockade has improved the prognosis of recurrent and/or metastatic head and neck squamous cell carcinoma (R/M HNSCC), but response rates remain low. In this study, we aimed to investigate the prognostic value of CRP and its early kinetics to predict response and survival in R/M HNSCC.A total of 87 patients who received first-line pembrolizumab for R/M HNSCC were analyzed. Three-fold cross-validation was used to estimate cut-off points of CRP at baseline and on-treatment (day 40 ± 10). Treatment response and survival were analyzed according to early CRP kinetics. The neutrophil-to-lymphocyte ratio (NLR) was used as a benchmark for the prognostic performance of CRP.On-treatment CRP below 2 mg/dl, 4x the upper limit of normal (ULN), was associated with increased overall survival (OS), while on-treatment CRP below 3 mg/dl (6x ULN) was correlated with a higher disease control rate (DCR) and increased progression-free survival (PFS). CRP flare-responders and CRP responders showed a higher DCR and longer PFS than CRP non-responders. An NLR above 6 was a negative prognosticator for progression. In multivariable analysis, on-treatment CRP prevailed as the only significant prognosticator for OS (HR: 4.97, CI95%: 2.18-11.32, p < 0.001) and PFS (HR: 2.07, CI95%: 1.07-3.99, p = 0.030).On-treatment CRP was identified as a prognostic biomarker for objective response and survival in R/M HNSCC patients receiving first-line pembrolizumab and could be easily incorporated into clinical practice as a widely available and cost-effective biomarker." @default.
• W4386020163 created "2023-08-22" @default.
• W4386020163 creator A5004872477 @default.
• W4386020163 creator A5011774727 @default.
• W4386020163 creator A5014740286 @default.
• W4386020163 creator A5014910334 @default.
• W4386020163 creator A5019227870 @default.
• W4386020163 creator A5034274700 @default.
• W4386020163 creator A5037593755 @default.
• W4386020163 creator A5052684427 @default.
• W4386020163 creator A5085607838 @default.
• W4386020163 date "2023-08-21" @default.
• W4386020163 modified "2023-10-09" @default.
• W4386020163 title "Early on-treatment C-reactive protein and its kinetics predict survival and response in recurrent and/or metastatic head and neck cancer patients receiving first-line pembrolizumab" @default.
• W4386020163 cites W2019607817 @default.
• W4386020163 cites W2152575748 @default.
• W4386020163 cites W2162347139 @default.
• W4386020163 cites W2592144107 @default.
• W4386020163 cites W2604665624 @default.
• W4386020163 cites W2613669325 @default.
• W4386020163 cites W2751884637 @default.
• W4386020163 cites W2767789104 @default.
• W4386020163 cites W2811088815 @default.
• W4386020163 cites W2922097565 @default.
• W4386020163 cites W2936722831 @default.
• W4386020163 cites W2975889253 @default.
• W4386020163 cites W2986633517 @default.
• W4386020163 cites W3014525423 @default.
• W4386020163 cites W3017049470 @default.
• W4386020163 cites W3026899880 @default.
• W4386020163 cites W3047138337 @default.
• W4386020163 cites W3130129495 @default.
• W4386020163 cites W3171893145 @default.
• W4386020163 cites W4214898940 @default.
• W4386020163 cites W4220938104 @default.
• W4386020163 cites W4229444610 @default.
• W4386020163 doi "https://doi.org/10.1007/s10637-023-01388-x" @default.
• W4386020163 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/37603206" @default.
• W4386020163 hasPublicationYear "2023" @default.
• W4386020163 type Work @default.
• W4386020163 citedByCount "0" @default.
• W4386020163 crossrefType "journal-article" @default.
• W4386020163 hasAuthorship W4386020163A5004872477 @default.
• W4386020163 hasAuthorship W4386020163A5011774727 @default.
• W4386020163 hasAuthorship W4386020163A5014740286 @default.
• W4386020163 hasAuthorship W4386020163A5014910334 @default.
• W4386020163 hasAuthorship W4386020163A5019227870 @default.
• W4386020163 hasAuthorship W4386020163A5034274700 @default.
• W4386020163 hasAuthorship W4386020163A5037593755 @default.
• W4386020163 hasAuthorship W4386020163A5052684427 @default.
• W4386020163 hasAuthorship W4386020163A5085607838 @default.
• W4386020163 hasBestOaLocation W43860201631 @default.
• W4386020163 hasConcept C121608353 @default.
• W4386020163 hasConcept C126322002 @default.
• W4386020163 hasConcept C143998085 @default.
• W4386020163 hasConcept C185592680 @default.
• W4386020163 hasConcept C2776530083 @default.
• W4386020163 hasConcept C2776833033 @default.
• W4386020163 hasConcept C2776914184 @default.
• W4386020163 hasConcept C2777701055 @default.
• W4386020163 hasConcept C2780057760 @default.
• W4386020163 hasConcept C2780739268 @default.
• W4386020163 hasConcept C2781195455 @default.
• W4386020163 hasConcept C2781197716 @default.
• W4386020163 hasConcept C3019894029 @default.
• W4386020163 hasConcept C55493867 @default.
• W4386020163 hasConcept C71924100 @default.
• W4386020163 hasConcept C90924648 @default.
• W4386020163 hasConceptScore W4386020163C121608353 @default.
• W4386020163 hasConceptScore W4386020163C126322002 @default.
• W4386020163 hasConceptScore W4386020163C143998085 @default.
• W4386020163 hasConceptScore W4386020163C185592680 @default.
• W4386020163 hasConceptScore W4386020163C2776530083 @default.
• W4386020163 hasConceptScore W4386020163C2776833033 @default.
• W4386020163 hasConceptScore W4386020163C2776914184 @default.
• W4386020163 hasConceptScore W4386020163C2777701055 @default.
• W4386020163 hasConceptScore W4386020163C2780057760 @default.
• W4386020163 hasConceptScore W4386020163C2780739268 @default.
• W4386020163 hasConceptScore W4386020163C2781195455 @default.
• W4386020163 hasConceptScore W4386020163C2781197716 @default.
• W4386020163 hasConceptScore W4386020163C3019894029 @default.
• W4386020163 hasConceptScore W4386020163C55493867 @default.
• W4386020163 hasConceptScore W4386020163C71924100 @default.
• W4386020163 hasConceptScore W4386020163C90924648 @default.
• W4386020163 hasFunder F4320323437 @default.
• W4386020163 hasIssue "5" @default.
• W4386020163 hasLocation W43860201631 @default.
• W4386020163 hasLocation W43860201632 @default.
• W4386020163 hasOpenAccess W4386020163 @default.
• W4386020163 hasPrimaryLocation W43860201631 @default.
• W4386020163 hasRelatedWork W2062691140 @default.
• W4386020163 hasRelatedWork W2517747645 @default.
• W4386020163 hasRelatedWork W2521234799 @default.
• W4386020163 hasRelatedWork W2585407512 @default.
• W4386020163 hasRelatedWork W2891524425 @default.
• W4386020163 hasRelatedWork W2945780494 @default.
• W4386020163 hasRelatedWork W3037068108 @default.
• W4386020163 hasRelatedWork W3041652591 @default.

• next